AH Bio Fund II, L.P., 10% Owner at Scribe Therapeutics, Inc. (SCTX), bought 333,333 shares at $15.00 ($5.0M) on 2026-07-27, disclosed to the SEC on 2026-07-29.
AH Bio Fund II, L.P. purchased 333,333 shares for $5.0M at $15.00, marking the largest insider purchase in the company's history. This significant capital commitment suggests high conviction in the company's genetic editing technology following its recent IPO.
Scribe Therapeutics is currently trading at $18.46, a 6.31% premium to its 52-week low of $17.37, but remains down 27.05% from its 52-week high of $25.31. The stock has surged 30% since its IPO on July 24, 2026.
1) Q1 earnings on July 30, 2026, to validate the commercial potential of the new genetic editing therapies. 2) The completion of three clinical trials testing whether one-time treatments can halve the risk of heart attacks and strokes, funded by the $125 million raised in the IPO. 3) The company's debut at $25 on July 24, 2026, with a valuation of $440.3 million, backed by major pharma investors Sanofi and Eli Lilly.
1) The stock is currently trading 27.05% below its 52-week high of $25.31, indicating significant volatility and potential downside risk. 2) The company is a pre-revenue biotech with no analyst coverage yet, making it highly sensitive to clinical trial results and execution risk.
Negative factors outweigh the positive ones.